Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

BACKGROUND: The addition of high-dose cytarabine to the treatment of mantle cell lymphoma (MCL) has significantly prolonged survival of patients, but relapses are common and are normally associated with increased resistance. To elucidate the mechanisms responsible for cytarabine resistance, and to c...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Freiburghaus, Catja, Emruli, Venera Kuci, Johansson, Angelica, Eskelund, Christian Winther, Grønbæk, Kirsten, Olsson, Roger, Ek, Fredrik, Jerkeman, Mats, Ek, Sara
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2018
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5918903/
https://ncbi.nlm.nih.gov/pubmed/29695239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4346-1
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires